Autopsy report · NCT01848652

Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.

“The laboratory's partner on this study decides to terminate the contract with the CHRU Brest, because of the difficulty of the recruitment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 1 year 7 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University Hospital, Brest

Sponsor type

University, hospital or other

Conditions

Cerebral Lymphoma B Cell Refractory

Interventions

infusion of MYOCET

Participants

5

Sites

3

Countries

France

Trials that died the same way

• Long-term Extension Study of MCI-196
  “This study has been terminated because of insufficient patient recruitment.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.